- Data will be presented as an oral presentation at EHA on Thursday, June 12, 2025, and at ICML on Thursday, June 19, 2025BOULDER, Colo., June 10, 2025 /PRNewswire/ -- Foresight Diagnostics, a leading developer of ultra-sensitive minimal residual disease (MRD) detection technologies, today announced that validation data demonstrating the prognostic performance of its CLARITY™ MRD assay in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) will be featured as encore oral presentations at two upcoming international conferences: the 2025 European Hematology Association (EHA) Congress (June 12–15, in Milan, Italy) and the 18th International Conference on Malignant Lymphoma (ICML) (June 17–21, in Lugano, Switzerland).This multi-center study, conducted in collaboration with Amsterdam University Medical Centers, the Hemato-Oncology Foundation for Adults in the Netherlands (HOVON), and the Netherlands Comprehensive Cancer Organization (IKNL), highlights real-world results using Foresight CLARITY™ MRD on patients who were treated with frontline chemotherapy across over 50 centers in the Netherlands and Belgium."We're grateful to present our data at major medical meetings this spring, validating our science and the real-world utility of ultra-sensitive ctDNA-MRD technology," said David Kurtz, M.D., Ph.D., Chief Medical Officer of Foresight Diagnostics. "These presentations and the recent incorporation of ctDNA-MRD testing in B-cell lymphoma clinical guidelines give us confidence as we prepare to launch in the clinical market in 2026 and integrate Foresight CLARITY into routine clinical practice."Lead study authors Steven Wang, M.D., and Martine Chamuleau, M.D., Ph.D., Amsterdam UMC, added: "Our findings confirm that ultra-sensitive ctDNA-MRD detection provides meaningful prognostic information beyond standard imaging and clinical factors. We believe this assay can support better risk stratification than imaging alone and inform post-treatment management decisions in DLBCL."Oral presentation details for EHA:Title: Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trialPresenter: Martine Chamuleau, MD, PhD (Amsterdam UMC)Session: Aggressive Non-Hodgkin lymphoma - Clinical (Observational)Time: Thursday, June 12 | 5:00 p.m. – 5:15 p.m. CEST / 11:00 a.m. – 11:15 a.m

Simultaneously, Qiagen N.V. (NYSE:QGEN) is partnering with Foresight Diagnostics to create a kit-based version of the CLARITY NGS assay, a cutting-edge circulating tumor DNA test for lymphoma.

The data shows the prognostic value of Foresight CLARITY MRD detection at the end of frontline DLBCL in one of its largest prospective, real-world studies to dateData will be presented as an oral presentation on Friday, May 30, 2025 , at 2:45 p.m. CTBOULDER, Colo., May 22, 2025 /PRNewswire/ -- Foresight Diagnostics, Inc. ("Foresight"), a leading diagnostics company specializing in the development of ultra-sensitive minimal residual disease (MRD) detection, today announced the presentation of independent validation data demonstrating the prognostic performance of its Foresight CLARITY™ MRD assay in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). The results will be shared in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 31 to June 3, 2025, in Chicago, Illinois.The prospective, multi-center observational study, led by Amsterdam UMC in close collaboration with the Hemato-Oncology Foundation for Adults in the Netherlands (HOVON) and Netherlands Comprehensive Cancer Organization (IKNL), is the largest independent validation study of Foresight CLARITY to date, spanning more than 150 patients with frontline DLBCL treated uniformly with curative-intent therapy across 50 sites in the Netherlands and Belgium.Key Findings:ctDNA-MRD was detected at end of treatment (EOT) in 24% of patients; 76% were MRD-negative.MRD-positive patients showed significantly lower progression-free survival (28% vs. 88%) and overall survival (50% vs. 97%) compared to MRD-negative patients.Among patients who were MRD-negative and achieved PET complete response at EOT, 2-year progression-free survival (PFS) and overall survival (OS) were 91% and 99%, respectively.All patients who failed to achieve complete response by PET and remained MRD-positive experienced relapse.ctDNA-MRD remained a powerful independent predictor of outcomes across multiple clinical subgroups, even after adjusting for standard prognostic factors."These results provide important prospective validation of Foresight CLARITY's clinical performance in frontline DLBCL across a large, real-world patient cohort," said David Kurtz, M.D., Chief Medical Officer of Foresight Diagnostics